Parabilis Medicines, Inc.
- Last sale
- Nov 12, 2026 · -6.49%
- Market cap
- $3.38B
- 122.08M shares
- Filings
- 65
Q3 2026
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026−44.7% FY25 yoy
- $3.38B
- —
- —
- 3.4×
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Parabilis Medicines, Inc. is the 71st largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ELVNEnliven Therapeutics, Inc.———$3.6BAMLXAmylyx Pharmaceuticals, Inc.$0.0100.0%—$3.5BVKTXViking Therapeutics, Inc.$0.0——$3.5BVRDNViridian Therapeutics, Inc.$70.8M23,359.9%483.6%$3.5BSUPNSupernus, Inc.$1.2B4.3%16.9%$3.4BLEGNLegend Biotech Corp$1.0B64.0%28.8%$3.4B
PBLSParabilis Medicines, Inc. (this company)———$3.4B
ARQTArcutis Biotherapeutics, Inc.$376.1M91.3%4.3%$3.3BDYNDyne Therapeutics, Inc.———$3.2BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Parabilis Medicines, Inc. · CIK 1657677 · Engraved from SEC EDGAR